On Thursday, Following U.S. Stocks were among the “Top Gainers”: SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), Vail Resorts Inc. (NYSE:MTN), TASER International Inc. (NASDAQ:TASR), Penn Virginia Corporation (NYSE:PVA)

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN), with shares inclined 9.80%, closed at $8.85.

Vail Resorts, Inc. (NYSE:MTN), with shares jumped 9.72%, settled at $93.27.

TASER International, Inc. (NASDAQ:TASR), with shares climbed 9.38%, and closed at $24.13.

Penn Virginia Corporation (NYSE:PVA), surged 8.99%, and closed at $7.03.

Latest NEWS regarding these Stocks are depicted underneath:

SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)

SciClone Pharmaceuticals, Inc. (SCLN), stated financial results for the fourth quarter and year ended December 31, 2014.

Proceeds in the fourth quarter of 2014 were $41.4 million, an $8.7 million or 26.6% raise, contrast to $32.7 million for the same period in 2013. For the year ended December 31, 2014, proceeds were $134.8 million, contrast to proceeds of $127.1 million last year. ZADAXIN® proceeds were $39.0 million in the fourth quarter of 2014, an $8.5 million or 27.9% raise, contrast to $30.5 million for the same period in 2013. ZADAXIN proceeds were $126.1 million for the year ended December 31, 2014, a $29.8 million or 30.9% raise, contrast to $96.3 million last year. Promotion services proceeds were $0.7 million for the fourth quarter of 2014, a $0.1 million or 15% decrease, contrast to $0.8 million in the same period in 2013. Promotion services proceeds were $2.8 million for the year ended December 31, 2014, contrast to $27.6 million last year. SciClone’s promotion services proceeds for the fourth quarter and year ended December 31, 2014 were negatively affected by the expiration of the promotion contracts with Sanofi Aventis S.A. (“Sanofi”) when their terms ended on December 31, 2013.

On a GAAP basis, SciClone stated net revenue in the fourth quarter of 2014 of $3.5 million, or $0.07 per share on both a basic and diluted basis, contrast to net revenue of about $36,000, or $0.00 per share on both a basic and diluted basis, for the same period in 2013. SciClone’s net revenue for the year ended December 31, 2014 was $25.2 million, or $0.49 and $0.48 per share on a basic and diluted basis, respectively, contrast with net revenue of $11.0 million, or $0.20 per share on both a basic and diluted basis, for 2013.

SciClone’s non-GAAP net revenue in the fourth quarter of 2014 was $15.4 million, or $0.30 and $0.29 per share on a basic and diluted basis, respectively, contrast with non-GAAP net revenue of $4.0 million, or $0.08 and $0.07 per share on a basic and diluted basis, respectively, for the same period of the preceding year. SciClone’s non-GAAP net revenue for the year ended December 31, 2014, was $39.7 million, or $0.77 and $0.75 per share on a basic and diluted basis, respectively, contrast with non-GAAP net revenue of $23.2 million, or $0.43 and $0.42 per share on a basic and diluted basis, respectively, for last year.

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical corporation, provides therapies for the treatment of oncology, infectious diseases, and cardiovascular disorders primarily in the People’s Republic of China.

Vail Resorts Inc. (NYSE:MTN)

Vail Resorts Inc. (MTN), stated results for the second quarter of fiscal 2015 ended January 31, 2015 and the Corporation’s ski season-to-date metrics through March 8, 2015.

Highlights:

• Resort Stated EBITDA raised 32.2% for the second quarter of fiscal 2015 contrast to the same period in the preceding year.
• Net revenue attributable to Vail Resorts, Inc. was $115.8 million for the second fiscal quarter of 2015, representing a 95.3% raise contrast to the same period in the preceding year.
• The Corporation updated its fiscal 2015 guidance with Resort Stated EBITDA predictable to be between $340 million and $350 million, not including the $16.4 million non-cash gain related to the Park City litigation settlement, which remains within the Corporation’s initial guidance range.
• The Corporation has repaid all borrowings under the revolver portion of its credit facility used to finance the $182.5 million attainment of Park City Mountain Resort (“Park City”) in September 2014.
• The Corporation’s Board of Directors approved a 50% raise in the quarterly cash dividend to $0.6225 per share from $0.4150 per share starting with the dividend payable on April 15, 2015 to stockholders of record as of March 31, 2015.
• The Corporation intends to refinance the remaining $215.0 million of its 6.50% Senior Subordinated Notes due 2019 (“6.50% Notes”) and the aggregate $41.2 million of the 6.95% Eagle County Bonds with a $250.0 million term loan under its existing senior credit facility, which we expect will result in about $12 million in pre-tax annual interest savings at current rates.

Vail Resorts, Inc., through its auxiliaries, operates mountain resorts and urban ski areas in the United States. The corporation operates in three segments: Mountain, Lodging, and Real Estate. Vail Resorts Development Corporation is the real estate planning, development and construction partner of Vail Resorts, Inc. Vail Resorts is a publicly held corporation traded on the New York Stock Exchange (MTN).

TASER International Inc. (NASDAQ:TASR)

TASER International Inc. (TASR), declared multiple orders of its TASER® brand next generation Smart Weapons and Conducted Electrical Weapons (CEWs). These orders were received in the first quarter and are predictable to be shipped in the first quarter of 2015.

TASER International, Inc. is engaged in the development, manufacture, and sale of conducted electrical weapons (CEWs) for use in law enforcement, federal, military, corrections, private security, and personal defense markets worldwide.

Penn Virginia Corporation (NYSE:PVA)

Formerly on February 18, Penn Virginia Corporation (PVA), offered its 2015 capital plan and guidance, declared year-end 2014 proved oil and gas reserves and offered an update of its operations, counting fourth quarter 2014 operational results.

Full-Year 2015 Capital Plan and Guidance:

Capital Expenditures

Capital expenditures are predictable to be $295 to $345 million, a decrease of 57% to 63% from 2014, with 60% to 65% of the expenditures being incurred during the first half of the year.

Drilling and completion capital expenditures, which will be focused on the Upper Eagle Ford, are predictable to be $270 to $310 million.

Pipeline, gathering, facilities, seismic and other capital expenditures are predictable to be $10 to $15 million.

Lease attainment capital expenditures are predictable to be $15 to $20 million.

We expect drilling and completion capital expenditures to range between $6.0 and $7.5 million per well for wells with two strings of casing, assuming 15 to 25 frac stages, and between $6.5 and $10.5 million per well for 3-string wells, assuming 12 to 33 frac stages. We expect 2015 drilling and completion costs to decrease from 2014 as a result of:

A decrease in the number of frac stages per well from an average of 26.5 stages during 2014 to an average of 22 stages in 2015, with the distance between stages increasing from 225 feet to 250 feet.

A reduction in the amount of proppant per stage to about 300,000 lbs. from an average of about 360,000 lbs. in 2014.

A decrease of 10% to 20% in completion costs over 2014 levels as a result of renegotiated service sector costs, in addition to the adjustments to the completion design as explained above.

An ongoing improvement in operational execution of the drilling and completion program.

Penn Virginia Corporation (PVA) is an independent oil and gas corporation engaged in the exploration, development and production of oil, natural gas liquids and natural gas in various domestic onshore regions of the United States, with a primary focus in the Eagle Ford Shale in south Texas.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.